ECSP17008187A - Formas de dosificación farmacéutica - Google Patents

Formas de dosificación farmacéutica

Info

Publication number
ECSP17008187A
ECSP17008187A ECIEPI20178187A ECPI201708187A ECSP17008187A EC SP17008187 A ECSP17008187 A EC SP17008187A EC IEPI20178187 A ECIEPI20178187 A EC IEPI20178187A EC PI201708187 A ECPI201708187 A EC PI201708187A EC SP17008187 A ECSP17008187 A EC SP17008187A
Authority
EC
Ecuador
Prior art keywords
dosage forms
pharmaceutical dosage
fluorobenzonitrile
pyrrolo
imidazol
Prior art date
Application number
ECIEPI20178187A
Other languages
English (en)
Inventor
Beato Stefania
QUINTON Peggy
Original Assignee
Productos Familia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Familia Sa filed Critical Productos Familia Sa
Publication of ECSP17008187A publication Critical patent/ECSP17008187A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosificación farmacéutica para administración oral que comprenden el fármaco 4-[(5R)-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-5-il]-3-fluorobenzonitrilo o cualquier sal farmacéuticamente aceptable del mismo y a procesos para producir dichas formas sólidas de dosificación farmacéutica.
ECIEPI20178187A 2014-07-07 2017-02-10 Formas de dosificación farmacéutica ECSP17008187A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
ECSP17008187A true ECSP17008187A (es) 2018-03-31

Family

ID=53610933

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20178187A ECSP17008187A (es) 2014-07-07 2017-02-10 Formas de dosificación farmacéutica

Country Status (29)

Country Link
US (2) US10143680B2 (es)
EP (2) EP3412278A1 (es)
JP (2) JP6731136B2 (es)
KR (1) KR102468610B1 (es)
CN (1) CN106470704B (es)
AR (1) AR101116A1 (es)
AU (1) AU2015287336B2 (es)
BR (1) BR112016030243B1 (es)
CA (1) CA2954393C (es)
CL (1) CL2017000026A1 (es)
CY (1) CY1120749T1 (es)
DK (1) DK3166596T3 (es)
EA (2) EA201991359A1 (es)
EC (1) ECSP17008187A (es)
ES (1) ES2686704T3 (es)
HR (1) HRP20181406T1 (es)
HU (1) HUE039037T2 (es)
IL (1) IL249374B (es)
LT (1) LT3166596T (es)
MX (1) MX2016017315A (es)
PE (1) PE20170201A1 (es)
PH (1) PH12016502540A1 (es)
PL (1) PL3166596T3 (es)
PT (1) PT3166596T (es)
SG (1) SG11201610227TA (es)
SI (1) SI3166596T1 (es)
TN (1) TN2016000557A1 (es)
TW (1) TWI707682B (es)
WO (1) WO2016005880A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3787623A1 (en) 2018-05-03 2021-03-10 Damian Pharma AG R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2680684A1 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2h)-pyrimidinyl]methyl]-4-fluorobenzonitrile
SI2523731T1 (sl) 2010-01-14 2019-02-28 Novartis Ag Uporaba sredstva, ki modificira adrenalni hormon
WO2012027731A2 (en) * 2010-08-27 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RU2617510C2 (ru) * 2011-09-08 2017-04-25 Новартис Аг Фармацевтические композиции, содержащие ингибитор ароматазы
AP2014007762A0 (en) * 2012-01-17 2014-07-31 Novartis Ag New forms and salts of a dihydropyrrolo[1,2C]imidazolyl aldosterone synthase or aromatase inhibitor
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
EP2836228B1 (en) 2012-04-12 2024-03-20 Novartis AG Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
AU2015287336A1 (en) 2017-01-12
US20170202808A1 (en) 2017-07-20
CN106470704A (zh) 2017-03-01
CA2954393A1 (en) 2016-01-14
US10709691B2 (en) 2020-07-14
TN2016000557A1 (en) 2018-04-04
EA201790140A1 (ru) 2017-05-31
WO2016005880A1 (en) 2016-01-14
US10143680B2 (en) 2018-12-04
HRP20181406T1 (hr) 2018-10-19
CY1120749T1 (el) 2019-12-11
MX2016017315A (es) 2017-04-27
PE20170201A1 (es) 2017-04-08
IL249374B (en) 2021-09-30
IL249374A0 (en) 2017-02-28
EP3166596A1 (en) 2017-05-17
AR101116A1 (es) 2016-11-23
CL2017000026A1 (es) 2017-07-28
SI3166596T1 (sl) 2018-10-30
ES2686704T3 (es) 2018-10-19
CN106470704B (zh) 2020-07-31
JP6731136B2 (ja) 2020-07-29
EA033685B1 (ru) 2019-11-15
HUE039037T2 (hu) 2018-12-28
LT3166596T (lt) 2018-09-25
SG11201610227TA (en) 2017-01-27
JP2017520590A (ja) 2017-07-27
KR102468610B1 (ko) 2022-11-21
AU2015287336B2 (en) 2018-06-14
EP3166596B1 (en) 2018-06-06
PT3166596T (pt) 2018-10-19
TWI707682B (zh) 2020-10-21
DK3166596T3 (en) 2018-09-10
BR112016030243B1 (pt) 2023-04-11
BR112016030243A2 (pt) 2017-08-22
US20190060283A1 (en) 2019-02-28
KR20170029491A (ko) 2017-03-15
CA2954393C (en) 2022-07-19
PH12016502540A1 (en) 2017-04-10
EA201991359A1 (ru) 2020-03-13
TW201613586A (en) 2016-04-16
EP3412278A1 (en) 2018-12-12
JP2019194221A (ja) 2019-11-07
PL3166596T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
BR112017028140A2 (pt) formulações farmacêuticas
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12016501841A1 (en) Immunosuppressant formulation
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
ECSP17008187A (es) Formas de dosificación farmacéutica
AR110374A1 (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
UY36474A (es) Método para producir liposomas que contienen un ingrediente farmacéutico activo
BR112017022335A2 (pt) combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
NI202000017A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
ES2472040R1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
AR106645A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX2016017312A (es) Composición farmacéutica de solifenacina en una tableta por comprension directa para su administración oral, para el tratamiento de alopatías relacionadas al mal funcionamiento de la vejiga.
BR112018009482A2 (pt) composto, método para preparar um composto, e, composição farmacêutica.
AR103730A1 (es) Método para la administración de droga
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
ITUB20153076A1 (it) Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento.